Confluence Genetics launched Cas-CLEAR, a CRISPR-based therapeutic platform that employs Cas12a2 nucleases to recognize cancer-specific genetic signatures and, upon target recognition, trigger broad collateral cleavage of cellular DNA and RNA — selectively killing cells…
Waypoint Bio emerged from stealth with a $20M Series A financing to advance multiple CAR-T investigator-initiated trials in China while developing an AI-enabled spatial pooled screening platform for next-generation target discovery.
Inhibrx Biosciences reported interim Phase 2 data for INBRX-106 in combination with Keytruda in first-line head and neck squamous cell carcinoma (HNSCC), suggesting potential costimulatory benefit beyond PD-1 monotherapy.
Terremoto Biosciences has raised $108 million in a Series C financing to advance its covalent targeted protein degradation platform, including AKT1-targeting degraders into clinical development.
Cartherics and Catalent have expanded their manufacturing partnership to support development and commercialization of iPSC-derived CAR-NK cell therapies. The agreement strengthens access to Catalent’s cGMP-compliant iPSC platform, supporting multiple programs including lead candidate CTH-401.What…
Gilead Sciences has agreed to acquire German biotech Tubulis in a deal worth up to $5 billion, significantly expanding its antibody-drug conjugate (ADC) platform capabilities. The transaction underscores the strategic importance of ADC technologies…
